The research looked at patients who qualified for the antiviral through age or health conditions. Those who took it shortly after infection were 26 percent less likely to have symptoms 90 days later.
Major data gaps, the result of decades of underinvestment in public health, have undercut the government response to the coronavirus and now to monkeypox.